



March 8, 2017

Arena Pharmaceuticals to Present at the 27th Annual Oppenheimer Healthcare Conference

SAN DIEGO, March 8, 2017 /PRNewswire/ -- [Arena Pharmaceuticals, Inc.](#) (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced that Amit Munshi, the Company's President and Chief Executive Officer will present a corporate update at the 27th Annual Oppenheimer Healthcare Conference on Wednesday, March 22 at 10:55am ET. The conference will take place March 21-22 at the Westin New York Grand Central in New York, NY.

A live audio webcast of the presentation will be available under the [investor relations](#) section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event.

About Arena Pharmaceuticals

[Arena Pharmaceuticals](#) is a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas. Arena is focused on three primary proprietary investigational [clinical programs](#): [etrasimod](#) (APD334) in Phase 2 evaluation for multiple autoimmune conditions, [ralinepag](#) (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH), and [APD371](#) entering Phase 2 evaluation for the treatment of pain associated with Crohn's disease. In addition, Arena has collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the upcoming presentation; and Arena's focus, primary programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact: Arena Pharmaceuticals, Inc.
Kevin R. Lind, Chief Financial Officer
klind@arenapharm.com
858.210.3636



To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-the-27th-annual-oppenheimer-healthcare-conference-300420578.html>

SOURCE Arena Pharmaceuticals, Inc.

News Provided by Acquire Media